title: Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells.
abstract: The absorption of commonly used ferrous iron salts from intestinal segments at neutral to slightly alkaline pH is low, mainly because soluble ferrous iron is easily oxidized to poorly soluble ferric iron and because ferrous iron, but not ferric iron, is carried by the divalent metal transporter DMT-1. Moreover, ferrous iron frequently causes gastrointestinal side effects. Iron hydroxide nanoparticles with neutral and hydrophilic carbohydrate shells are alternatively used to ferrous salts. In these formulations gastrointestinal side effects are rare because hundreds of ferric iron atoms are safely packed in nanoscaled cores surrounded by the solubilizing shell; nevertheless, iron bioavailability is even worse compared to ferrous salts. In this study the cell uptake of iron hydroxide and iron oxide nanoparticles (FeONP) with negatively charged shells of different chemical types and sizes was compared to the uptake of those with neutral hydrophilic shells, ferrous sulfate and ferric chloride. The nanoparticle uptake was measured in Caco-2 cells with the iron detecting ferrozine method and visualized by transmission electron microscopy. The toxicity was evaluated using the MTT assay. For nanoparticles with a negatively charged shell the iron uptake was about 40 times higher compared to those with neutral hydrophilic carbohydrate shell or ferric chloride and in the same range as ferrous sulfate. However, in contrast to ferrous sulfate, nanoparticles with negatively charged shells showed no toxicity. Two different uptake mechanisms were proposed: diffusion for hydroxide nanoparticles with neutral hydrophilic shell and adsorptive endocytosis for nanoparticles with negatively charged shells. It needs to be determined whether iron hydroxide nanoparticles with negatively charged shells also show improved bioavailability in iron-deficient patients compared to iron hydroxide nanoparticles with a neutral hydrophilic shell, which exist in the market today.
authors.affiliation: Department of Biopharmacy and Pharmaceutical Technology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.
authors.forename: Markus R
authors.initials: MR
authors.lastname: Jahn
authors.forename: Thomas
authors.initials: T
authors.lastname: Nawroth
authors.forename: Sören
authors.initials: S
authors.lastname: Fütterer
authors.forename: Uwe
authors.initials: U
authors.lastname: Wolfrum
authors.forename: Ute
authors.initials: U
authors.lastname: Kolb
authors.forename: Peter
authors.initials: P
authors.lastname: Langguth
mesh_terms: D018938:Caco-2 Cells; D002712:Chlorides / Q000737:chemistry; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure
chemical_list: D002712:Chlorides; D005290:Ferric Compounds; C000499:ferric oxide; C021024:ferric hydroxide; C024555:ferric chloride